Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | CAPRICOR THERAPEUTICS, INC. |
|---|---|
| Ticker | CAPR |
| CIK | 0001133869 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,49 Mrd. USD |
| Beta | 0,48 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -105,043,946 | -2.26 | 355,949,294 | 305,792,145 |
| 2025-09-30 | 10-Q | -24,570,647 | -0.54 | 126,438,207 | 83,867,255 | |
| 2025-06-30 | 10-Q | -25,910,791 | -0.57 | 133,569,011 | 104,977,056 | |
| 2025-03-31 | 10-Q | -24,391,594 | -0.53 | 153,765,973 | 127,645,467 | |
| 2024-12-31 | 10-K | 22,270,465 | -40,467,186 | -1.15 | 170,481,086 | 145,462,336 |
| 2024-09-30 | 10-Q | 2,261,642 | -12,556,728 | -0.38 | 92,951,613 | 68,264,959 |
| 2024-06-30 | 10-Q | 3,971,438 | -10,999,782 | -0.35 | 38,277,453 | 11,502,306 |
| 2024-03-31 | 10-Q | 4,906,877 | -9,794,073 | -0.31 | 49,444,442 | 18,434,938 |
| 2023-12-31 | 10-K | 25,178,066 | -22,287,542 | -0.83 | 58,734,327 | 22,601,467 |
| 2023-09-30 | 10-Q | 6,185,814 | -6,390,608 | -0.25 | 37,152,330 | -1,787,656 |
| 2023-06-30 | 10-Q | 3,917,467 | -7,366,579 | -0.29 | 46,011,198 | 2,731,163 |
| 2023-03-31 | 10-Q | 2,986,696 | -7,768,266 | -0.31 | 53,863,409 | 6,206,249 |
| 2022-12-31 | 10-K | 2,551,469 | -29,019,532 | -1.18 | 50,094,910 | 11,786,094 |
| 2022-09-30 | 10-Q | 1,591,566 | -6,371,115 | -0.26 | 53,928,107 | 15,426,492 |
| 2022-06-30 | 10-Q | -7,109,411 | -0.29 | 58,065,574 | 18,728,995 | |
| 2022-03-31 | 10-Q | -7,818,094 | -0.32 | 64,921,918 | 24,642,666 | |
| 2021-12-31 | 10-K | 244,898 | -20,022,520 | -0.87 | 41,330,323 | 31,367,966 |
| 2021-09-30 | 10-Q | 244,898 | -3,931,807 | -0.17 | 43,100,521 | 36,735,970 |
| 2021-06-30 | 10-Q | 204,082 | -4,748,266 | -0.21 | 39,930,052 | 33,380,130 |
| 2021-03-31 | 10-Q | 40,816 | -5,151,923 | -0.23 | 43,544,401 | 36,380,785 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Sabar Karimah Es | Director | Open Market Sale | -7,529 | 32.00 | -240,928.00 | -22,9% | |
| 2026-04-01 | Sabar Karimah Es | Director | Open Market Sale | -53,735 | 31.03 | -1,667,225.10 | -158,4% | |
| 2026-03-31 | Krasney Karen | Officer, EVP, GENERAL COUNSEL | Open Market Sale | -25,000 | 30.12 | -752,935.00 | -71,5% | |
| 2026-03-31 | Sabar Karimah Es | Director | Open Market Sale | -61,265 | 30.17 | -1,848,242.52 | -175,6% | |
| 2026-03-31 | Bergmann Anthony | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -25,000 | 30.13 | -753,152.50 | -71,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.